Saniona Dirección

Dirección controles de criterios 2/4

El CEO de Saniona's es Thomas Feldthus , nombrado en Apr 2022, tiene una permanencia de 2.08 años. compensación anual total es SEK2.88M, compuesta por 45.6% salario y 54.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.87% de las acciones de la empresa, por valor de SEK1.76M. La antigüedad media del equipo directivo y de la junta directiva es de 2.3 años y 8.7 años, respectivamente.

Información clave

Thomas Feldthus

Chief Executive Officer (CEO)

kr4.0m

Compensación total

Porcentaje del salario del CEO	60.7%
Permanencia del CEO	2.1yrs
Participación del CEO	0.9%
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	7.5yrs

Actualizaciones recientes de la dirección

Recent updates

What Type Of Shareholders Make Up Saniona AB (publ)'s (STO:SANION) Share Registry?

Jan 06

Is Saniona (STO:SANION) Using Too Much Debt?

Dec 02

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Thomas Feldthus en comparación con los beneficios de Saniona?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-kr96m
Sep 30 2023	n/a	n/a	-kr108m
Jun 30 2023	n/a	n/a	-kr66m
Mar 31 2023	n/a	n/a	-kr134m
Dec 31 2022	kr3m	kr1m	-kr245m
Sep 30 2022	n/a	n/a	-kr334m
Jun 30 2022	n/a	n/a	-kr445m
Mar 31 2022	n/a	n/a	-kr461m
Dec 31 2021	n/a	n/a	-kr411m
Sep 30 2021	n/a	n/a	-kr326m
Jun 30 2021	n/a	n/a	-kr280m
Mar 31 2021	n/a	n/a	-kr200m
Dec 31 2020	n/a	n/a	-kr73m
Sep 30 2020	n/a	n/a	-kr25m
Jun 30 2020	n/a	n/a	-kr5m
Mar 31 2020	n/a	n/a	-kr751k
Dec 31 2019	kr2m	kr2m	-kr69m
Sep 30 2019	n/a	n/a	-kr96m
Jun 30 2019	n/a	n/a	-kr53m
Mar 31 2019	n/a	n/a	-kr52m
Dec 31 2018	kr2m	kr2m	-kr41m
Sep 30 2018	n/a	n/a	-kr32m
Jun 30 2018	n/a	n/a	-kr61m
Mar 31 2018	n/a	n/a	-kr56m
Dec 31 2017	kr2m	kr2m	-kr49m

Compensación vs. Mercado: La compensación total de Thomas($USD367.36K) está por encima de la media de empresas de tamaño similar en el mercado Swedish ($USD247.85K).

Compensación vs. Ingresos: La compensación de Thomas ha aumentado mientras la empresa no es rentable.

CEO

Thomas Feldthus (63 yo)

2.1yrs

Permanencia

kr3,981,000

Compensación

Mr. Thomas Feldthus, M.Sc., MBA, served as Independent Director at Scandion Oncology A/S since 2018 until May 25, 2022. He serves as Chief Executive Officer at Saniona AB (publ) since April 30, 2022. He co...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jorgen Drejer	Founder	10.3yrs	kr412.00k	2.13% SEK 4.3m
Thomas Feldthus	Co-Founder & CEO	2.1yrs	kr3.98m	0.87% SEK 1.7m
Anita Milland	Chief Financial Officer	2.1yrs	sin datos	0.030% SEK 60.2k
Karin Nielsen	Chief Scientific Officer	8.2yrs	sin datos	0.19% SEK 379.6k
Palle Christophersen	Executive Vice President of Research	2.3yrs	kr1.38m	0.67% SEK 1.3m
Janus Larsen	Chief Development Officer	2.3yrs	sin datos	0.26% SEK 516.6k

2.3yrs

Permanencia media

59yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de SANION se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jorgen Drejer	Founder	10.3yrs	kr412.00k	2.13% SEK 4.3m
Carl Sundberg	Independent Director	8.7yrs	kr430.00k	0.045% SEK 89.5k
Anna Ljung	Independent Director	6.3yrs	kr496.00k	0.0042% SEK 8.3k
Pierandrea Muglia	Independent Director	less than a year	kr117.00k	sin datos

7.5yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de SANION se considera experimentada (8.6 años de antigüedad promedio).

Saniona Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Saniona AB (publ), Annual General Meeting, May 29, 2024

Saniona AB Appoints Nomination Committee for the Annual General Meeting 2023

Insufficient new directors

Insufficient new directors

Saniona Appoints Anita Milland as Chief Financial Officer, Effective April 30, 2022

President & CEO recently bought kr100k worth of stock

Recent updates

Saniona AB (publ) to Report Fiscal Year 2023 Results on Apr 30, 2024

Full year 2023 earnings released: kr1.49 loss per share (vs kr3.93 loss in FY 2022)

New major risk - Shareholder dilution

Price target decreased by 37% to kr6.00

Saniona Announces the Selection of Its Proprietary GABAA A5 Negative Allosteric Modulator (NAM) Lead Compound, San2465

Saniona AB (publ) Strengthens Epilepsy Pipeline with Selection of SAN2355 as Clinical Candidate

Third quarter 2023 earnings released: kr0.38 loss per share (vs kr0.28 profit in 3Q 2022)

Saniona AB (publ) to Report Fiscal Year 2024 Results on Feb 27, 2025

Saniona AB (publ), Annual General Meeting, May 29, 2024

Saniona (STO:SANION) Is Making Moderate Use Of Debt

Saniona Promotes Kv7 Epilepsy Compound to Candidate Selection Phase

Second quarter 2023 earnings released: kr0.34 loss per share (vs kr1.42 loss in 2Q 2022)

New minor risk - Shareholder dilution

Is Saniona (STO:SANION) Using Too Much Debt?

First quarter 2023 earnings released: kr0.35 loss per share (vs kr2.14 loss in 1Q 2022)

Full year 2022 earnings released: kr3.93 loss per share (vs kr6.59 loss in FY 2021)

Saniona AB Appoints Nomination Committee for the Annual General Meeting 2023

Third quarter 2022 earnings released: EPS: kr0.28 (vs kr1.50 loss in 3Q 2021)

Saniona AB (publ) to Report Q1, 2023 Results on May 25, 2023

Insufficient new directors

Saniona AB (publ) Announces Anti-Inflammatory and Anti-Fibrotic Candidate SAN903 Is Ready for Clinical Studies

Second quarter 2022 earnings released: kr1.42 loss per share (vs kr1.67 loss in 2Q 2021)

Saniona Progresses Its Kv7 Epilepsy Program into Lead Optimization

Saniona Reports Positive Top Line Results from the SAN711 Phase 1 Clinical Trial

Insufficient new directors

Saniona’S Preclinical Candidate San903 Shows Robust Dampening of Fibrosis in Chronic Kidney Disease Model

Saniona Provides Update on Ongoing Review of Tesofensine in Mexico

Saniona Appoints Anita Milland as Chief Financial Officer, Effective April 30, 2022

Saniona Announces Voluntary Pause of Phase 2B Clinical Trials of Tesomet for Hypothalamic Obesity and Prader-Willi Syndrome

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Saniona AB (publ) to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Saniona Initiates Multiple Ascending Dose Stage of SAN711 Phase 1 Clinical Trial

Saniona Initiates Phase 2b Clinical Trial of Tesomet for Prader-Willi Syndrome

President & CEO recently bought kr100k worth of stock

Independent Chairman of the Board recently bought kr229k worth of stock

Third quarter 2021 earnings released: kr1.50 loss per share (vs kr1.24 loss in 3Q 2020)

Second quarter 2021 earnings released: kr1.67 loss per share (vs kr1.24 loss in 2Q 2020)

Saniona Initiates Phase 1 Clinical Trial of SAN711

Saniona to Present Preclinical Data on SAN711 at the 7th Congress of the European Academy of Neurology

First quarter 2021 earnings released: kr1.34 loss per share (vs kr1.47 profit in 1Q 2020)

Full year 2020 earnings released: kr1.79 loss per share (vs kr2.95 loss in FY 2019)

Is Saniona (STO:SANION) Using Too Much Debt?

Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity

Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Prader-Willi Syndrome

New 90-day low: kr18.70

Need To Know: Saniona AB (publ) (STO:SANION) Insiders Have Been Buying Shares

Novartis AG (SWX:NOVN) completed the acquisition of Cadent Therapeutics, Inc. from a group of sellers.

New 90-day low: kr20.10

What Type Of Shareholders Make Up Saniona AB (publ)'s (STO:SANION) Share Registry?

New 90-day low: kr20.70

Saniona Announces Management Appointments

Co-Founder recently bought kr108k worth of stock

Co-Founder recently bought kr115k worth of stock

New 90-day low: kr22.55

Is Saniona (STO:SANION) Using Too Much Debt?

Third quarter 2020 earnings released: kr1.24 loss per share

Saniona AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

Saniona AB (publ) Appoints Nomination Committee Members

Saniona Reports Positive Topline Results from Tesomet Phase 2 Open-Label Extension Study in Hypothalamic Obesity

New 90-day low: kr24.70

Saniona Receives Pre-IND Feedback from FDA on Regulatory Path for Tesomet in Prader-Willi Syndrome (PWS) and Hypothalamic Obesity (HO)

Earnings released

Saniona AB (publ) has completed a Follow-on Equity Offering in the amount of $64.999993 million.

New 90-day high - kr42.50

An unknown buyer acquired 3.96% stake in Scandion Oncology A/S (NGM:SCOL) from Saniona AB (publ) (OM:SANION) for for $2.3 million.

New 90-day high - kr29.30

Análisis de compensación del CEO

CEO

Permanencia